查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654366

全球 HIV 診斷市場：市場規模、市場佔有率、趨勢分析（按產品、模式、測試類型、最終用途和地區）、細分市場預測（2025-2030 年）

HIV Diagnostics Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Mode (Self-test), By Test Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

HIV 診斷市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，全球愛滋病毒診斷市場預計到 2030 年將達到 15.5 億美元，2025 年至 2030 年期間的複合年成長率為 5.0%。

這一市場成長的主要驅動力是對開發更敏感的 HIV 診斷 POC 測試的需求不斷成長，這種測試可以在資源有限的環境中輕鬆在照護端進行。檢測技術的發展預計將在預測期內引入大量新的快速 POC 檢測，這是推動 HIV 診斷市場成長的主要因素。此外，政府針對愛滋病毒發起的計劃和宣傳活動、全球衛生保健工作為降低該疾病的流行率所做的努力以及中東和東部地區市場存在大量未滿足的需求，都是有望有利於未來成長機會的一些關鍵因素。

HIV 診斷市場：概覽

  • 抗體檢測領域將主導產業，到 2024 年將佔據 56.6% 的最大收益佔有率。這一巨大佔有率可以透過這些測試的高市場使用率和普及率來解釋，這些測試包括 ELISA、家用乾血斑、蛋白質印跡測試 IFA 和 RIPA。這些測試具有高度敏感性和準確性，因此最常用於篩檢和確認 HIV-1 和 HIV-2。
  • 病毒量檢測和 CD4 檢測也將在 2024 年佔據相當大的市場。這些測試更加敏感、快速且便於攜帶，能夠快速到達照護現場（POC），從而提高了資源貧乏的愛滋病毒感染地區的市場效用和可及性。
  • 預測期內，目前正在臨床開發和主要企業產品平臺中的多種新型 POC HIV 診斷產品預計將實現商業化。預計預測期內此類產品的興起將推動該市場的成長。
  • 預計亞太地區愛滋病診斷產業在預測期內將呈現顯著的成長率。該地區研發的進步是愛滋病診斷市場發展的主要動力。
  • 預計拉丁美洲愛滋病診斷市場將在整個預測期內實現顯著成長。愛滋病診斷市場的發展受到該地區愛滋病相關死亡人數下降的推動，過去十年來，拉丁美洲愛滋病相關死亡人數下降了 28%，加勒比地區下降了 57%。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第3章 HIV 診斷市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • HIV 診斷市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章 HIV 診斷市場：按產品的估計和趨勢分析

  • 按產品市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球 HIV 診斷市場：產品展望
  • 市場規模預測及趨勢分析（2018-2030年）
    • 耗材
    • 裝置
    • 軟體和服務

第 5 章：愛滋病毒診斷市場：按模式進行的估計和趨勢分析

  • 按模式分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球愛滋病毒診斷市場：按模式展望
  • 市場規模預測及趨勢分析（2018-2030年）
    • 自我檢測
    • 實驗室為基礎

第 6 章 HIV 診斷市場：按測試類型進行的估計和趨勢分析

  • 按測試類型分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球 HIV 診斷市場：按檢測類型分類的展望
  • 市場規模預測及趨勢分析（2018-2030年）
    • 抗體檢測
    • 病毒量測試
    • CD4 偵測
    • 其他

第 7 章：愛滋病毒診斷市場：按最終用途的估計和趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球 HIV 診斷市場：依最終用途分類的前景
  • 市場規模預測及趨勢分析（2018-2030年）
    • 診斷實驗室
    • 醫院和診所
    • 居家醫療

第 8 章：愛滋病毒診斷市場：按地區分類的估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2030 年）
  • 細分儀表板
  • 全球愛滋病毒診斷市場：區域展望
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要企業市場佔有率（2024年）
    • Alere Inc.
    • Abbott
    • Bristol-Myers Squibb Company
    • Janssen Global Services, LLC
    • Gilead Sciences, Inc.
    • Merck &Co. Inc.
    • VIIV Healthcare
    • BD
    • Beckman Coulter, Inc.
    • Sysmex Europe SE
    • Apogee Flow Systems
    • Point Care
    • Zyomtronix, Inc.
    • Mylan NV
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthcare GmbH
    • QIAGEN
Product Code: 978-1-68038-461-1

HIV Diagnostics Market Growth & Trends:

The global HIV diagnostics market size is estimated to reach USD 1.55 billion by 2030, expanding at a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key factors accounting for the growth of this market include the growing need in for the development of more sensitive HIV diagnostic point of care tests which can be easily implemented at the location of patient care in resource-limited settings. Technological development of tests which is expected to introduce a number of novel rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. Furthermore, government programs and campaigns initiated against HIV, global healthcare efforts to reduce disease incidence, and the presence of high unmet demand in the Middle Eastern and Eastern regions of the market are some key factors expected to serve as lucrative future growth opportunities.

HIV Diagnostics Market Report Highlights:

  • The antibody test segment dominated the industry and accounted for the largest revenue share of 56.6% in 2024. This large share can be accounted for by the high market usage and penetration rates of these tests which include, ELISA, home access dried blood spot, western blot testing IFA, and RIPA. These tests are highly sensitive and accurate and thus are most commonly used for screening and confirmation of HIV-1 & HIV-2.
  • Viral Load testing and CD4 testing also accounted for a considerable share of the market in 2024. There is a prevalent in the market for the development of these tests which will make them more sensitive, rapid in nature, and portable to the point of care to enhance their market usability and accessibility in resource-limited HIV-affected regions.
  • It is expected that during the forecast period, a number of novel point-of-care HIV diagnostic products will be commercialized which are currently under clinical development and in product pipelines of key market players. This increase in the range of products is expected to fuel the growth of this market over the forecast period.
  • The Asia Pacific HIV diagnostics industry is expected to experience a notable growth rate during the forecast period. Advancements in research and development in the region are significant drivers for the HIV diagnostics market.
  • The Latin America HIV diagnostics industry is expected to experience significant growth throughout the forecast period. The HIV diagnostics market is driven by the region's progress in reducing HIV-related deaths, which have declined by 28% in Latin America and 57% in the Caribbean over the past decade.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Mode
    • 1.2.3. Test Type
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Mode outlook
    • 2.2.3. Test type outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. HIV Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Advancements in Diagnostic Technologies
      • 3.2.1.2. Government Initiatives to Increase Accessibility
      • 3.2.1.3. Rising HIV Awareness and Screening Programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Advanced Diagnostics
      • 3.2.2.2. Stigma and Social Barriers
  • 3.3. HIV Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. HIV Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global HIV Diagnostics Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Consumables
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Software and Services
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. HIV Diagnostics Market: Mode Estimates & Trend Analysis

  • 5.1. Mode Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global HIV Diagnostics Market by Mode Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Self-test
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Lab-based
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. HIV Diagnostics Market: Test Type Estimates & Trend Analysis

  • 6.1. Test Type Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global HIV Diagnostics Market by Test Type Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Antibody Test
      • 6.4.1.1. HIV-1 Screening Tests
        • 6.4.1.1.1. ELISA/EIA
          • 6.4.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.1.2. Home Access Dried Blood Spot
          • 6.4.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
          • 6.4.1.1.2.2. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.1.3. Rapid Tests (Dot plot, Agglutination Tests)
          • 6.4.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.2. HIV-1 Antibody Confirmatory Tests
        • 6.4.1.2.1. Western Blot Test
          • 6.4.1.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.2.2. Indirect Immunofluorescent Antibody Assay (IFA)
          • 6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.2.3. Line Immunoassay
          • 6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.2.4. RadioImmunoPrecipitation Assay (RIPA)
          • 6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.3. HIV-2 & Group O Diagnostic Tests
        • 6.4.1.3.1. Blood Antibody Tests
          • 6.4.1.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.3.2. Dried Blood Spot (DBS) Test
          • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.3.3. Others and (Oral, Urine)
          • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Viral load test
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.3. CD4 test
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.4. Others
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 7. HIV Diagnostics Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global HIV Diagnostics Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Diagnostic Laboratories
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. Hospitals & Clinics
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.3. Home Settings
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 8. HIV Diagnostics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Target disease prevalence
      • 8.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Target disease prevalence
      • 8.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Target disease prevalence
      • 8.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Target disease prevalence
      • 8.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Target disease prevalence
      • 8.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Target disease prevalence
      • 8.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Target disease prevalence
      • 8.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Target disease prevalence
      • 8.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Target disease prevalence
      • 8.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Target disease prevalence
      • 8.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Target disease prevalence
      • 8.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Target disease prevalence
      • 8.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Target disease prevalence
      • 8.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. Target disease prevalence
      • 8.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Target disease prevalence
      • 8.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Target disease prevalence
      • 8.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Target disease prevalence
      • 8.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Target disease prevalence
      • 8.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
      • 8.8.1.6. )
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Target disease prevalence
      • 8.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. Target disease prevalence
      • 8.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Target disease prevalence
      • 8.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Target disease prevalence
      • 8.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Target disease prevalence
      • 8.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company market share analysis, 2024
    • 9.3.2. Alere Inc.
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Abbott
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Bristol-Myers Squibb Company
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Janssen Global Services, LLC
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Gilead Sciences, Inc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Merck & Co. Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. VIIV Healthcare
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. BD
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Beckman Coulter, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Sysmex Europe SE
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Apogee Flow Systems
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Point Care
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Zyomtronix, Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Mylan N.V.
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. F. Hoffmann-La Roche Ltd.
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives
    • 9.3.17. Siemens Healthcare GmbH
      • 9.3.17.1. Company overview
      • 9.3.17.2. Financial performance
      • 9.3.17.3. Product benchmarking
      • 9.3.17.4. Strategic initiatives
    • 9.3.18. QIAGEN
      • 9.3.18.1. Company overview
      • 9.3.18.2. Financial performance
      • 9.3.18.3. Product benchmarking
      • 9.3.18.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 4 North America HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 5 North America HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 8 U.S HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 9 U.S HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 10 Canada HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 11 Canada HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 12 Canada HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 13 Canada HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Mexico HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 15 Mexico HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 16 Mexico HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 Mexico HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Europe HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 19 Europe HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 20 Europe HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 Europe HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 UK HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 23 UK HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 24 UK HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 25 UK HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Germany HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 27 Germany HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 28 Germany HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Germany HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 30 France HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 31 France HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 32 France HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 33 France HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Italy HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 35 Italy HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 36 Italy HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 37 Italy HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Spain HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 39 Spain HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 40 Spain HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 41 Spain HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 42 Denmark HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 43 Denmark HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 44 Denmark HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 45 Denmark HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 46 Sweden HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 47 Sweden HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 48 Sweden HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Sweden HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Norway HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 51 Norway HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 52 Norway HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 53 Norway HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 58 Japan HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 59 Japan HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 60 Japan HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 61 Japan HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 62 China HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 63 China HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 64 China HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 65 China HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 66 India HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 67 India HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 68 India HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 69 India HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 70 Australia HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 71 Australia HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 72 Australia HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 73 Australia HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 74 Thailand HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 75 Thailand HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 76 Thailand HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 77 Thailand HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 78 South Korea HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 79 South Korea HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 80 South Korea HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 81 South Korea HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Latin America HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 83 Latin America HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 84 Latin America HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 85 Latin America HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Brazil HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 87 Brazil HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 88 Brazil HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 89 Brazil HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 90 Argentina HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 91 Argentina HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 92 Argentina HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 93 Argentina HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Middle East & Africa HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 95 Middle East & Africa HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 96 Middle East & Africa HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 97 Middle East & Africa HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 98 South Africa HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 99 South Africa HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 100 South Africa HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 101 South Africa HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 102 Saudi Arabia HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 103 Saudi Arabia HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 104 Saudi Arabia HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 105 Saudi Arabia HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 106 UAE HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 107 UAE HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 108 UAE HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 109 UAE HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 110 Kuwait HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 111 Kuwait HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 112 Kuwait HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 113 Kuwait HIV diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 HIV Diagnostics: Market outlook
  • Fig. 9 HIV Diagnostics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 HIV Diagnostics Market driver impact
  • Fig. 15 HIV Diagnostics Market restraint impact
  • Fig. 16 HIV Diagnostics Market strategic initiatives analysis
  • Fig. 17 HIV Diagnostics market: Product movement analysis
  • Fig. 18 HIV Diagnostics market: Product outlook and key takeaways
  • Fig. 19 Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Software and Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 HIV Diagnostics market: Mode movement analysis
  • Fig. 23 HIV Diagnostics market: Mode outlook and key takeaways
  • Fig. 24 Self-test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Lab-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 HIV Diagnostics market: Test type movement analysis
  • Fig. 27 HIV Diagnostics market: Test type outlook and key takeaways
  • Fig. 28 Antibody Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 HIV-1 Screening Tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 ELISA/EIA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Home Access Dried Blood Spot market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Rapid Tests (Dot plot, Agglutination Tests) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 HIV-1 Antibody Confirmatory Tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Western Blot Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Indirect Immunofluorescent Antibody Assay (IFA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Line Immunoassay market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 RadioImmunoPrecipitation Assay (RIPA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 HIV-2 & Group O Diagnostic Tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Blood Antibody Tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Dried Blood Spot (DBS) Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Others and (Oral, Urine) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Viral load test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 CD4 test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 HIV Diagnostics market: End Use movement analysis
  • Fig. 46 HIV Diagnostics market: End Use outlook and key takeaways
  • Fig. 47 Diagnostic Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Hospitals & Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Home Settings market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 North America HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 U.S HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Canada HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Europe HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 UK HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Germany HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 France HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Italy HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Spain HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Sweden HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Norway HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Denmark HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Japan HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 China HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 India HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Australia HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Latin America HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Brazil HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Argentina HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Middle East and Africa HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Saudi Arabia HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 South Africa HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 UAE HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)